Upcoming CPACS trial is allcomers cardio protect anti-cancer. For labelling purposes this would have to result in statistically significant results in both cardio protect and anti-cancer. Otherwise labelling will be akin to Dexrazoxane (merely cardio protection), which wouldn't maximise value. Or if P2 results in a narrow CPACS target then gives the option to label under single indication.
To top this off its not just anti-cancer in breast cancer but also a basket trial of cancers. So what? If you missed it the bigger play is also FTO inhibition proof-of-concept. To correlate anti-cancer to m6A will get pharma excited so perhaps DrT hasn't yet conceded Cardio protect as being the bigger elephant, happy to be corrected.
The way i see it is, Cardio protect will open the door and FTO will seal the deal. Race could have just undertaken a Breast cancer CPACS trial, but why not? Race would have Oncolines FTO data to correlate anti-cancer effect in-vitro results of Dox+Bisantrene. If not, Race would effectively be adding in a secondary endpoint as a guess, not sure that is how clinical trials are designed and tested by scientists?
@Anydaynow the trials in south korea and hong kong are not by chance. Its a geographical license play starting off at the small end then China (big end) before US (end game / exit). My thoughts only - DYOR. Great questions, but just a reminder Hotcopper isnt a Q&A you need to do your own research and come to your own conclusions, the answers are there.
- Forums
- ASX - By Stock
- RAC
- Cardioprotection thread
Cardioprotection thread, page-712
-
- There are more pages in this discussion • 194 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.56 |
Change
0.010(0.65%) |
Mkt cap ! $265.8M |
Open | High | Low | Value | Volume |
$1.55 | $1.56 | $1.51 | $95.69K | 62.25K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 3015 | $1.55 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.56 | 4018 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 3015 | 1.550 |
2 | 17973 | 1.530 |
1 | 19190 | 1.525 |
1 | 20000 | 1.520 |
1 | 500 | 1.500 |
Price($) | Vol. | No. |
---|---|---|
1.560 | 4018 | 1 |
1.570 | 4602 | 2 |
1.580 | 15715 | 3 |
1.600 | 2319 | 1 |
1.645 | 10000 | 1 |
Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online